RecruitingNot ApplicableNCT06390878

Nationwide Research on the Rewilding of Kindergarten Yards

Nationwide Research on the Rewilding of Kindergarten Yards - Vahvistu


Sponsor

Natural Resources Institute Finland

Enrollment

320 participants

Start Date

May 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children. The investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children. Our specific aims are: To assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms. Assess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).


Eligibility

Min Age: 1 YearMax Age: 5 Years

Inclusion Criteria1

  • Attendance in kindergarten

Exclusion Criteria1

  • Use of antibiotics in the year before sampling

Interventions

OTHERBiodiversity

In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.

OTHERPlayground equipment

Playground equipment that increase the physical activity of children will be added to the kindergarten yards.


Locations(2)

Natural Resources Institute Finland

Helsinki, Uusimaa, Finland

Tampere University

Tampere, Finland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06390878


Related Trials